While enzalutamide inhibited the proliferation of prostate cancer cell lines with a 5-fold difference in IC50 values between AR-positive and -negative prostate cancer cell lines, it inhibited TNBC cell lines at comparable concentrations regardless of the AR expression. The gene discussed is AR; the disease is prostate cancer.